Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Liabilities: 2009-2025

Historic Total Liabilities for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to $638.4 million.

  • Amicus Therapeutics' Total Liabilities rose 5.04% to $638.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $638.4 million, marking a year-over-year increase of 5.04%. This contributed to the annual value of $591.0 million for FY2024, which is 4.33% down from last year.
  • Amicus Therapeutics' Total Liabilities amounted to $638.4 million in Q3 2025, which was up 4.48% from $611.0 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Total Liabilities registered a high of $638.4 million during Q3 2025, and its lowest value of $559.1 million during Q1 2021.
  • In the last 3 years, Amicus Therapeutics' Total Liabilities had a median value of $611.0 million in 2025 and averaged $610.7 million.
  • In the last 5 years, Amicus Therapeutics' Total Liabilities soared by 68.28% in 2021 and then dropped by 4.33% in 2024.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Total Liabilities stood at $597.8 million in 2021, then rose by 0.56% to $601.1 million in 2022, then climbed by 2.76% to $617.7 million in 2023, then fell by 4.33% to $591.0 million in 2024, then grew by 5.04% to $638.4 million in 2025.
  • Its Total Liabilities stands at $638.4 million for Q3 2025, versus $611.0 million for Q2 2025 and $596.3 million for Q1 2025.